Abstract

Nitendra Rohit*, Aadarsh Richhariya and Dr. Yuvraj Singh Dangi

ABSTRACT

Due to the shortcomings of present TB therapy regimens, tuberculosis (TB) continues to be a common infectious illness worldwide despite substantial attempts to enhance treatment. Directly addressing host characteristics may be advantageous for the treatment of tuberculosis, according to recent research on innovative therapeutic approaches. These tactics, referred to as host-directed therapies (HDTs), centre on interactions between hosts and pathogens. HDTs may be more effective than the TB medications that are already on the market, which are constrained by the lengthy treatment times required and the rise of drug-resistant strains. Host factors like cytokines, immunological checkpoints, immune cell functions, and crucial enzyme activity are among the targets of HDTs.